The Lost Women of Science by Melina Gerosa Bellows and Katie Hafner is an exciting book for young readers that brings to life the stories of ten remarkable women who changed the world of science but have been forgotten, or written out of history completely. Published by Penguin Random House’s Bright Matter imprint, the book transforms podcast episodes into a collection of inspiring biographies written for middle school readers.

In this Lost Women of Science Conversation, Melina and Katie talk about their favorite female scientists and why their grit and determination can help inspire curiosity in the next generation of young female (and male) scientists. For parents, teachers or grandparents looking to spark a love of science in the young people in their lives, look no further than this book this holiday season.

In 2022, Susan Wojcicki was on top of the world—CEO of YouTube, parent to five kids, and running a few miles a day—when she received a shocking diagnosis: metastatic lung cancer. She soon resigned from YouTube and dedicated herself to fighting the disease and looking for answers. Why does the leading cause of cancer deaths receive less funding than some less lethal cancers? How could her lung cancer have progressed so far undetected? And how did Susan get lung cancer, when she had never smoked? This episode is dedicated to her.

In the 1910s, a relatively unknown cancer researcher named Maud Slye announced the first results of a study with the loftiest ambitions: to identify what causes cancer. To answer that question, the University of Chicago geneticist had bred tens of thousands of mice, enough to fill a three-story building. She carefully documented their ancestry and their morbidities and performed autopsies. And to Slye, her findings were clear: vulnerability to cancer was hereditary. If we wanted to, we could eliminate it. But Slye made some crucial mistakes along the way—and a number of enemies.

Composer Peter Hugh White and librettist Clare Heath join host Rosie Millard in front of a London audience to explore why the story of chemist and x-ray crystallographer Rosalind Franklin and the race to uncover the structure of DNA makes such a compelling subject for an opera.

We hear excerpts that capture the contrasting personalities at the centre of this scientific drama — James Watson, the brash young researcher at the University of Cambridge; Francis Crick, his more measured collaborator; and Maurice Wilkins, an anxious biophysicist uneasy about being outshone by his brilliant colleague, Franklin.

It’s a story of ambition, rivalry, and betrayal: Franklin’s departure from King’s College London and the subsequent publication of the double helix model by Watson and Crick, which was built on insights from her work — yet without giving her due recognition.

Although initial clinical trials of tamoxifen as a treatment of breast cancer were positive, Imperial Chemical Industries (ICI) did not believe this market would be commercially viable. The company had hoped for a contraceptive pill – tamoxifen didn’t work for that – not a cancer treatment. In 1972 the higher-ups at ICI decided to cancel the research.‍

But Dora Richardson, the chemist who had originally synthesized the compound, and her boss, Arthur Walpole, were convinced they were on to something important, something that could save lives. They continued the research in secret. Tamoxifen was eventually launched in 1973 and went on to become a global success, saving hundreds of thousands of lives. Dora Richardson’s role in its development, however, was overshadowed by her a male colleague and all but forgotten.

This Best Of episode first aired in October 2024 to coincide with Breast Cancer Awareness month. It is now also available in a Spanish adaptation, narrated by Laura Gómez.

Aunque los ensayos clínicos iniciales del tamoxifeno como tratamiento del cáncer de mama fueron positivos, Imperial Chemical Industries (ICI) no creía que este mercado fuera comercialmente viable. La compañía esperaba una píldora anticonceptiva (el tamoxifeno no funcionó para eso), no un tratamiento contra el cáncer. En 1972, los superiores del ICI decidieron cancelar la investigación. ‍ Pero Dora Richardson, la química que originalmente había sintetizado el compuesto, y su jefe, Arthur Walpole, estaban convencidos de que estaban en algo importante, algo que podría salvar vidas. Continuaron la investigación en secreto. El tamoxifeno se lanzó finalmente en 1973 y se convirtió en un éxito mundial, salvando cientos de miles de vidas. El papel de Dora Richardson en su desarrollo, sin embargo, fue eclipsado por su colega masculino y casi olvidado.

In the early 1960s, Dr. Dora Richardson synthesized a chemical compound that became one of the most important drugs to treat breast cancer: tamoxifen. Although her name is on the original patent, her contributions have been lost to history.

In the first episode of this two-part podcast, Katie Couric introduces us to Dora’s story, and we show how Lost Women of Science producer Marcy Thompson tracked down Dora’s firsthand account of the history of the drug’s development. This document, lost for decades, tells the story of how the compound was made and how Imperial Chemical Industries, where Richardson worked, almost terminated the project because the company was hoping to produce a contraceptive, not a cancer therapy.

This Best Of episode first aired in October 2024 to coincide with Breast Cancer Awareness month. It is now also available in a Spanish adaptation, narrated by Laura Gómez.

A principios de la década de los sesenta, la Dra. Dora Richardson sintetizó un compuesto químico que se convirtió en uno de los medicamentos más importantes para tratar el cáncer de mama: el tamoxifeno. Aunque su nombre aparece en la patente original, sus contribuciones fueron olvidadas por la historia. En el primer episodio de este podcast de dos partes, les contamos la historia de Dora y de cómo Marcy Thompson, productora de Lost Women of Science, rastreó su relato en primera persona sobre el desarrollo del medicamento. Este documento, perdido durante décadas, narra cómo se creó el compuesto y cómo la empresa Imperial Chemical Industries, donde trabajaba Richardson, estuvo a punto de cancelar el proyecto porque buscaba desarrollar un anticonceptivo, no una terapia contra el cáncer.